Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25209448 | 0.85 | USP30 (0.46) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL25615939 | 0.85 | USP30 (0.46) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL25615634 | 0.84 | USP30 (0.47) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL25212697 | 0.84 | USP30 (0.47) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL21422114 | 0.83 | USP30 (0.44) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL31496209 | 0.79 | USP30 (0.48) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL2799598 | 0.79 | USP30 (0.51) | USP30FFAR1GPR119 | |
| SCHEMBL22776955 | 0.78 | USP30 (0.50) | USP30FFAR1GPR119 | |
| SCHEMBL25255926 | 0.77 | USP30 (0.46) | USP30FFAR1GPR119NPBWR1MCHR1 | |
| SCHEMBL320828 | 0.77 | USP30 (0.52) | USP30FFAR1GPR119FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2019195201-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | USP30 251/4885FFAR1 4173/4885GPR119 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.